Literature DB >> 26222643

Management of toxicities following pelvic irradiation for gynaecological cancers.

Andreia Fernandes1, Neel J Bhuva, Alexandra Taylor.   

Abstract

PURPOSE OF REVIEW: With increasing numbers of cancer survivors, management of the consequences of treatment is a major clinical problem. This article discusses recent advances in preventing and managing radiotherapy-related toxicity. RECENT
FINDINGS: Often underreported in clinical studies, radiation toxicity should be assessed with validated assessment tools to assess impact on quality of life. Prevention strategies targeting reactive oxygen species and proinflammatory cytokines show promise. Bowel toxicity is the most common late effect, and algorithm-led investigation and management can significantly improve outcomes. Oral and intravesical therapies are options for bladder toxicity if conservative measures fail.
SUMMARY: With better understanding of the mechanisms of acute and chronic radiation-induced changes, more effective treatments are now possible. Following pelvic radiotherapy, patients should be proactively assessed for early intervention by a specialist multidisciplinary team.

Entities:  

Mesh:

Year:  2015        PMID: 26222643     DOI: 10.1097/CCO.0000000000000215

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  2 in total

1.  Gastrointestinal consequences of cancer treatment: evaluation of 10 years' experience at a tertiary UK centre.

Authors:  Radha Gadhok; Emma Paulon; Chehkuan Tai; Tomisin Olushola; John Barragry; Farooq Rahman; Simona Di Caro; Shameer Mehta
Journal:  Frontline Gastroenterol       Date:  2020-08-11

2.  Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women.

Authors:  Despina Tsementzi; Angela Pena-Gonzalez; Jinbing Bai; Yi-Juan Hu; Pretesh Patel; Joseph Shelton; Mary Dolan; Jessica Arluck; Namita Khanna; Lesley Conrad; Isabelle Scott; Tony Y Eng; Konstantinos T Konstantinidis; Deborah W Bruner
Journal:  Cancer Med       Date:  2020-04-01       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.